Nike has named David Denton, former CFO of Pfizer, as its new executive vice president and chief financial officer effective August 17. Denton will succeed Matthew Friend, who will stay until September 4 to assist with the transition. Denton brings extensive experience from Pfizer, Lowe's, and CVS Health, and is expected to help Nike focus on capital allocation, financial discipline, and long-term growth under CEO Elliott Hill's leadership. Analysts see this move as part of Nike's strategy to shift from foundational actions to disciplined execution amid ongoing challenges in key markets like China and Europe. Nike's fiscal Q4 results, due June 30, will include a tariff refund benefit not previously forecasted, though underlying results are expected to align with prior guidance.
During the 2026 World Cup across the U.S., Canada, and Mexico, non-sponsor brands such as Levi's, Nike, and Taco Bell gained significant attention through innovative and cheeky marketing strategies that resonated with fans. Despite FIFA's official sp...
Nike is at risk of being removed from the Dow Jones Industrial Average due to its low stock price. If this happens, Berkshire Hathaway could take Nike's place in the index. This change would be notable as Berkshire Hathaway has not been part of the D...
Nike is set to release its fiscal Q4 earnings on June 30, with shares currently near their 52-week and historical lows. The company faces challenges primarily due to ongoing weakness in its China market, which is its largest outside North America. De...
The global sports eyewear market, valued at $9.73 billion in 2025, is expected to reach $16.59 billion by 2033, growing at a CAGR of 6.9%. This growth is fueled by increased participation in fitness activities and outdoor sports, alongside rising awa...
